Please login to the form below

Not currently logged in
Email:
Password:

Invokana

This page shows the latest Invokana news and features for those working in and with pharma, biotech and healthcare.

AZ claims first-in-class win for Farxiga in heart failure

AZ claims first-in-class win for Farxiga in heart failure

At the same time, first-to-market SGLT2 inhibitor Invokana (canagliflozin) from Johnson &Johnson has been shrinking since the FDA added a label warning of lower-limb amputations risk in 2017.

Latest news

More from news
Approximately 20 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken Invokana (the 2nd entrant).

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including Janssen/Mitsubishi Tanabe's Invokana (canagliflozin), Sanofi/Chugai's tofogliflozin and

  • Pharma deals during April 2013 Pharma deals during April 2013

    Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its SGLT2 inhibitor—Invokana (canagliflozin). In this deal, Merck gets to extend the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics